posdinemab

From Aaushi
Jump to navigation Jump to search

Indications

* granted Fast Track designation by the FDA on Jan 8, 2025[1]

Dosage

Mechanism of action

More general terms

Additional terms

References

  1. Jump up to: 1.0 1.1 1.2 Mendoza B Posdinemab Granted Fast Track Designation by the FDA for Early Alzheimer Disease. Psych Congress Network. Jan 10, 2025 https://www.hmpgloballearningnetwork.com/site/pcn/posdinemab-granted-fast-track-designation-fda-early-alzheimer-disease
  2. Jump up to: 2.0 2.1 Galpern WR, Triana-Baltzer G, Li L et al Phase 1 Studies of the Anti-Tau Monoclonal Antibody JNJ-63733657 in Healthy Participants and Participants with Alzheimer's Disease. J Prev Alzheimers Dis. 2024;11(6):1592-1603. PMID: https://www.ncbi.nlm.nih.gov/pubmed/39559872 PMCID: PMC11573813 Free PMC article. Clinical Trial.